20-06-2023 Capital reduction of €65,000,000 · to €7,145,000 · repaid to the shareholders
02-01-2023 Capital increase of €65,000,000 · to €72,145,000 · no new shares · in cash
03-06-2020 Capital stated in the deed · €7,145,000 · 1,204,993 shares

Mandate history

59 people, 4 in office

All 59 In office 4 Ended 55

Board
Day-to-day management
Statutory auditor
Other function
began earlier
end not dated

Mandates per person, with start and end dates
Name	Functions and periods
Eduardo Marti Bofill	Director, appointed in the act of 17-09-2026, still in office
Sarah Bonhomme	Director, appointed in the act of 17-09-2026, still in office
Yan Sergerie	Director, appointed in the act of 17-09-2026, still in office
KPMG Réviseurs d'Entreprises	Statutory auditor, appointed in the act of 19-08-2022, still in office
Andrea Majocchi	Director, appointed in the act of 21-04-2022, until 01-08-2026
Federico Mambretti	Director, appointed in the act of 04-10-2021, until 01-08-2026
Nicolas Istas	Director, appointed in the act of 24-06-2021, until 21-09-2021 Director, appointed in the act of 19-08-2022, until 01-08-2026
Nicola Bencini	Director, appointed in the act of 21-04-2022, until 19-08-2022
PricewaterhouseCoopers Reviseurs d'Entreprises	Statutory auditor, appointed in the act of 27-08-2012, until 19-08-2022
Guy Oliver	Chair, appointed in the act of 04-10-2021, ended, last mentioned on 04-10-2021 Director, appointed in the act of 04-10-2021, until 01-03-2022
Nicolas Thiriet	Director, appointed in the act of 04-07-2019, until 01-03-2022 Secretaris van de raad van bestuur, appointed in the act of 04-07-2019, ended, last mentioned on 04-07-2019
Mark Never	Director, appointed in the act of 01-06-2018, until 21-09-2021
Philippe De Sorbier De Pougnadoresse	Director, until 10-06-2021
Knut Mager	Director, appointed in the act of 02-08-2016, until 19-05-2020
Dario Drago	Director, appointed in the act of 13-01-2017, until 06-06-2019
Antonis Sarlikiotis	Director, appointed in the act of 04-11-2013, until 01-11-2017 Director, until 01-11-2017
Philippe de Pougnadoresse	Director, appointed in the act of 10-08-2017, no longer listed in the 2025 annual accounts
Luc Beaulieu	Director, appointed in the act of 02-08-2016, until 01-06-2017 Directeur groep a, appointed in the act of 02-08-2016, ended, last mentioned on 13-01-2017
Annick D'Hont	Directiecomité, appointed in the act of 12-05-2017, last mentioned in 2017
Arnaud Loriers	Directeur groep b, appointed in the act of 02-08-2016, last mentioned in 2017
Christine Pilet	Business franchise head neuroscience, appointed in the act of 13-01-2017, last mentioned in 2017
Dany 'T Jampens	Head communication, appointed in the act of 27-08-2012, last mentioned in 2017
Evis Daci	Directeur groep b, appointed in the act of 02-08-2016, last mentioned in 2017
Evy Bierebeeck	Directeur groep b, appointed in the act of 02-08-2016, last mentioned in 2017
Marie Anne Van Lierde	Directeur groep b, appointed in the act of 02-08-2016, last mentioned in 2017
Michel Geelhand	Head public affairs, ma & dra, appointed in the act of 27-08-2012, last mentioned in 2017
Peter Goovaerts	Head human resources, appointed in the act of 27-08-2012, last mentioned in 2017
Pierre Leman	Head human resources, appointed in the act of 24-05-2013, last mentioned in 2017
Stefaan Vancayzeele	Head neuroscience & ms, appointed in the act of 27-08-2012, last mentioned in 2017
Tracy Goodridge	Oncology general manager, appointed in the act of 13-01-2017, last mentioned in 2017
Van Acker Francis	Head marketing primary care, appointed in the act of 05-08-2011, last mentioned in 2017
Emmanuel Collin	Head marketing & sales operations, appointed in the act of 27-08-2012, last mentioned in 2016
Hilde Johanna van der Kamp	Director, until 02-08-2016
Sue Webb	Director, appointed in the act of 24-05-2013, until 02-08-2016
Eric Comut	Director, until 04-11-2013
Eric Cornut	Director, from before 06-06-2011 to 01-04-2013
Jean-Claude Dubos	Director, from before 06-06-2011 to 06-12-2012
Robosa Gbinoba	Head qa, appointed in the act of 27-08-2012, until 01-09-2012
Fabrice Chouraqui	Financiële handtekeningbevoegdheid van groep a, appointed in the act of 28-06-2010, ended, last mentioned on 28-06-2010 Director, appointed in the act of 28-06-2010, until 01-04-2012 Board, until 27-08-2012
Gali Lesuisse	Head commercial effectiveness and productivity, appointed in the act of 05-08-2011, last mentioned in 2012
Hilde van der Kamp	Director, appointed in the act of 27-08-2012, last mentioned in 2012 Pharma division head belgium & country head belgium, appointed in the act of 27-08-2012, last mentioned in 2012
Jean-Marie Risselin	Head bu oncology, appointed in the act of 27-08-2012, last mentioned in 2012
Nele Van Malderen	Chief scientific officer, appointed in the act of 27-08-2012, last mentioned in 2012
Patricia van Dijck	Head market access & regulatory affairs, appointed in the act of 05-08-2011, last mentioned in 2012
Roeland Roelofs	Head ophta, appointed in the act of 27-08-2012, last mentioned in 2012
Romain Légé	Cfo, appointed in the act of 28-12-2011, last mentioned in 2012
Vinciane Vangeersdaele	Head iid, v&d, appointed in the act of 27-08-2012, last mentioned in 2012
Deborah Di Salvo	Head strategic marketing projects, until 05-08-2011
Kris Borgers	Head sales & marketing cns, appointed in the act of 14-04-2006, until 05-08-2011
Frederic Rodrigues Simoes	Cfo (chief financial officer), until 21-07-2011
Mimi de Ruyck	Head market access & regulatory affairs, until 31-01-2011
Tom Rossi	Director, appointed in the act of 03-07-2007, until 01-01-2010 Director, until 28-06-2010
Peter Jager	Director, appointed in the act of 03-07-2007, no longer listed in the 2025 annual accounts
Bertrand Bugnon	Cfo, appointed in the act of 14-04-2006, last mentioned in 2006
Erwin Schillinger	Chair of the board, appointed in the act of 14-04-2006, no longer listed in the 2025 annual accounts
Peter Van Reppelen	Head sales primary care, appointed in the act of 14-04-2006, last mentioned in 2006
Hans Horne	Director, appointed in the act of 13-02-2006, no longer listed in the 2025 annual accounts
Richard Brazier	Cfo (chief financial officer), until 01-02-2006
Ralph Zaat	Head b.u primary care & mature products, until 01-01-2006

Show all 59 people Show the first 12

Next steps

See this company's board, registered office and name on a given date.Company as of a date See what became of the directors' other companies.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file

Directors

Board 3

Statutory auditor 1

Owners and capital

Shareholders

Owners 2

Capital transactions

Mandate history

Next steps